Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Shuttle Pharmaceuticals Holdings, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 2 | $7.54 | $8.2 | $0.66 | 8.75% |
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Shuttle Pharmaceuticals Holdings, Inc. ever had a stock split?
Shuttle Pharmaceuticals Holdings, Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Christopher Robert Cooper CEO | NASDAQ (CM) Exchange | 825693401 CUSIP |
| US Country | 9 Employees | - Last Dividend | 11 Jun 2026 Last Split | 31 Aug 2022 IPO Date |
Overview
Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development of innovative therapies aimed at curing various types of cancers. Based in Gaithersburg, Maryland, the company is at the forefront of cancer therapy innovation, leveraging its scientific expertise to create treatments that aim to improve the efficacy of cancer care. By focusing on targeted therapies, Shuttle Pharmaceuticals Holdings, Inc. is dedicated to advancing the medical community's ability to fight cancer more effectively, offering hope to patients and families affected by this devastating disease.
Products and Services
Shuttle Pharmaceuticals Holdings, Inc. is involved in the development of a range of novel cancer treatments, each designed to address specific challenges in cancer therapy. The company's product pipeline includes:
- Ropidoxuridine: An oral halogenated pyrimidine developed to enhance the treatment of patients with brain tumors and sarcomas. This innovative drug is designed to increase the sensitivity of cancer cells to radiation, thereby improving the efficacy of traditional radiation therapy.
- SP-1-161: An HDAC inhibitor that targets the mutated ataxia-telangiectasia response pathway. This compound is engineered to sensitize cancer cells to radiation while simultaneously protecting normal cells, offering a dual-action approach to cancer therapy.
- SP-2-225: A pre-clinical class IIb compound with effects on the regulation of the immune system. This drug is under investigation for its potential to modulate the immune response in the context of cancer, aiming to enhance the body's natural ability to combat tumor growth.
- SP-1-303: A pre-clinical selective Class I HDAC inhibitor focused on the treatment of ER-positive cancers. This product represents a targeted approach to cancer therapy, seeking to exploit specific vulnerabilities in cancer cells to halt or reverse tumor progression.
